Pular para o conteúdo
Merck

Effect of butaclamol, a new neuroleptic, on serotoninergic mechanisms.

The Journal of pharmacy and pharmacology (1977-03-01)
T A Pugsley, W Lippmann
PMID15075
RESUMO

Butaclamol (1.0-0.1 mg kg-1, i.p.) and spiroperidol (1-0-0-5 mg kg-1, i.p.) but not (-)-butaclamol (15 mg kg-1, i.p.), blocked the hyperactivity induced in rats by tranylcypromine-L-tryptophan pretreatment. Neither butaclamol nor spiroperidol altered the accumulation of brain 5-HT following parglyine or the decline of brain 5-HT following inhibition with the tryptophan hydroxylase inhibitor alpha-propyldopacetamide thus indicating that butaclamol and spiroperidol do not affect either the synthesis or the turnover of brain 5-HT. It is concluded that the antagonism of the tranylcypromise-L-tryptophan-induced hyperactivity by butaclamol and spiroperidol is due to their blockade of dopaminergic receptors rather than an action on neuronal serotoninergic mechanisms.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
(−)-Butaclamol hydrochloride, solid